

Tobias Nordström

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9534392/publications.pdf>

Version: 2024-02-01

69
papers

2,918
citations

331670

21
h-index

189892

50
g-index

73
all docs

73
docs citations

73
times ranked

4841
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Cost-Effectiveness of the Stockholm3 Test and Magnetic Resonance Imaging in Prostate Cancer Screening: A Microsimulation Study. <i>European Urology</i> , 2022, 82, 12-19. | 1.9 | 4 |
| 2 | A Head-to-head Comparison of Prostate Cancer Diagnostic Strategies Using the Stockholm3 Test, Magnetic Resonance Imaging, and Swedish National Guidelines: Results from a Prospective Population-based Screening Study. <i>European Urology Open Science</i> , 2022, 38, 32-39. | 0.4 | 2 |
| 3 | Association of 5 α -Reductase Inhibitors With Prostate Cancer Mortality. <i>JAMA Oncology</i> , 2022, 8, 1019. | 7.1 | 18 |
| 4 | The Mount Sinai Prebiopsy Risk Calculator for Predicting any Prostate Cancer and Clinically Significant Prostate Cancer: Development of a Risk Predictive Tool and Validation with Advanced Neural Networking, Prostate Magnetic Resonance Imaging Outcome Database, and European Randomized Study of Screening for Prostate Cancer Risk Calculator. <i>European Urology Open Science</i> , 2022, 41, 45-54. | 0.4 | 4 |
| 5 | External Validation of the Prostate Biopsy Collaborative Group Risk Calculator and the Rotterdam Prostate Cancer Risk Calculator in a Swedish Population-based Screening Cohort. <i>European Urology Open Science</i> , 2022, 41, 1-7. | 0.4 | 4 |
| 6 | Combined Use of Prostate-specific Antigen Density and Magnetic Resonance Imaging for Prostate Biopsy Decision Planning: A Retrospective Multi-institutional Study Using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD). <i>European Urology Oncology</i> , 2021, 4, 971-979. | 5.4 | 56 |
| 7 | Predictors of adverse pathology on radical prostatectomy specimen in men initially enrolled in active surveillance for low-risk prostate cancer. <i>World Journal of Urology</i> , 2021, 39, 1797-1804. | 2.2 | 10 |
| 8 | Effect of information on prostate biopsy history on biopsy outcomes in the era of MRI-targeted biopsies. <i>World Journal of Urology</i> , 2021, 39, 1153-1159. | 2.2 | 2 |
| 9 | Biomarker discrimination and calibration with MRI-targeted biopsies: an analysis with the Stockholm3 test. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 457-464. | 3.9 | 1 |
| 10 | Incorporating Magnetic Resonance Imaging and Biomarkers in Active Surveillance Protocols - Results From the Prospective Stockholm3 Active Surveillance Trial (STHLM3AS). <i>Journal of the National Cancer Institute</i> , 2021, 113, 632-640. | 6.3 | 9 |
| 11 | Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. <i>Nature Genetics</i> , 2021, 53, 65-75. | 21.4 | 264 |
| 12 | The cost-effectiveness of prostate cancer screening using the Stockholm3 test. <i>PLoS ONE</i> , 2021, 16, e0246674. | 2.5 | 11 |
| 13 | Identifying Prostate Cancer Among Men with Lower Urinary Tract Symptoms. <i>European Urology Open Science</i> , 2021, 24, 11-16. | 0.4 | 2 |
| 14 | Head-to-head Comparison of Conventional, and Image- and Biomarker-based Prostate Cancer Risk Calculators. <i>European Urology Focus</i> , 2021, 7, 546-553. | 3.1 | 16 |
| 15 | Real world treatment utilization patterns in patients with castration-resistant prostate cancer. <i>Scandinavian Journal of Urology</i> , 2021, 55, 299-306. | 1.0 | 4 |
| 16 | Cost-Effectiveness of Magnetic Resonance Imaging in Prostate Cancer Screening: A Microsimulation Study. <i>Value in Health</i> , 2021, 24, 1763-1772. | 0.3 | 7 |
| 17 | MRI-Targeted or Standard Biopsy in Prostate Cancer Screening. <i>New England Journal of Medicine</i> , 2021, 385, 908-920. | 27.0 | 184 |
| 18 | Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial. <i>Lancet Oncology</i> , The, 2021, 22, 1240-1249. | 10.7 | 83 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Intensity of Active Surveillance and Transition to Treatment in Men with Low-risk Prostate Cancer. <i>European Urology Oncology</i> , 2020, 3, 640-647. | 5.4 | 15 |
| 20 | Prognostic value of perineural invasion in prostate needle biopsies: a population-based study of patients treated by radical prostatectomy. <i>Journal of Clinical Pathology</i> , 2020, 73, 630-635. | 2.0 | 9 |
| 21 | Effects of replacing PSA with Stockholm3 for diagnosis of clinically significant prostate cancer in a healthcare system – the Stavanger experience. <i>Scandinavian Journal of Primary Health Care</i> , 2020, 38, 315-322. | 1.5 | 19 |
| 22 | Association between PSA density and prostate cancer in men without significant MRI lesions. <i>BJU International</i> , 2020, 125, 763-764. | 2.5 | 8 |
| 23 | Lower urinary tract symptoms (LUTS) are not associated with an increased risk of prostate cancer in men 50–69 years with PSA ≤ 3 ng/ml. <i>Scandinavian Journal of Urology</i> , 2020, 54, 1-6. | 1.0 | 11 |
| 24 | Survival in patients diagnosed with castration-resistant prostate cancer: a population-based observational study in Sweden. <i>Scandinavian Journal of Urology</i> , 2020, 54, 115-121. | 1.0 | 36 |
| 25 | The economic burden of prostate cancer – a Swedish prevalence-based register study. <i>BMC Health Services Research</i> , 2020, 20, 448. | 2.2 | 19 |
| 26 | MRI-targeted biopsies in prostate cancer screening and the value of its combination with blood-based risk-prediction: The randomized, diagnostic study STHLM3MRI. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS378-TPS378. | 1.6 | 0 |
| 27 | Incorporating mpMRI and biomarkers in active surveillance protocols: The prospective Stockholm3 Active Surveillance trial (STHLM3AS). <i>Journal of Clinical Oncology</i> , 2020, 38, TPS379-TPS379. | 1.6 | 0 |
| 28 | Is there any association between prostate-specific antigen screening frequency and uptake of active surveillance in men with low or very low risk prostate cancer?. <i>BMC Urology</i> , 2019, 19, 73. | 1.4 | 0 |
| 29 | Salvage radiation therapy following radical prostatectomy in Stockholm County in 2008–2016. <i>Journal of Radiation Oncology</i> , 2019, 8, 225-231. | 0.7 | 0 |
| 30 | Association Between Antidiabetic Medications and Prostate-Specific Antigen Levels and Biopsy Results. <i>JAMA Network Open</i> , 2019, 2, e1914689. | 5.9 | 16 |
| 31 | Does a novel diagnostic pathway including blood-based risk prediction and MRI-targeted biopsies outperform prostate cancer screening using prostate-specific antigen and systematic prostate biopsies? - protocol of the randomised study STHLM3MRI. <i>BMJ Open</i> , 2019, 9, e027816. | 1.9 | 11 |
| 32 | Are Prostate Specific-Antigen (PSA) and age associated with the risk of ISUP Grade 1 prostate cancer? Results from 72 996 individual biopsy cores in 6 083 men from the Stockholm3 study. <i>PLoS ONE</i> , 2019, 14, e0218280. | 2.5 | 7 |
| 33 | A Unified Prostate Cancer Risk Prediction Model Combining the Stockholm3 Test and Magnetic Resonance Imaging. <i>European Urology Oncology</i> , 2019, 2, 490-496. | 5.4 | 13 |
| 34 | The impact of different prostate-specific antigen (PSA) testing intervals on Gleason score at diagnosis and the risk of experiencing false-positive biopsy recommendations: a population-based cohort study. <i>BMJ Open</i> , 2019, 9, e027958. | 1.9 | 15 |
| 35 | Improving GIS-based models for bicycling speed estimations. <i>Transportation Research Procedia</i> , 2019, 42, 85-99. | 1.5 | 2 |
| 36 | The Stockholm3 blood-test predicts clinically-significant cancer on biopsy: independent validation in a multi-center community cohort. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 137-142. | 3.9 | 20 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 37 | Reply to Erik Rud, Peter Lauritzen, and Eduard Baco's Letter to the Editor re: Henrik Grånberg, Martin Eklund, Wolfgang Pickett, et al. Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging. <i>Eur Urol</i> 2018;74:722-728. <i>European Urology</i> , 2019, 75, e104-e105. | 1.9 | 0 |
| 38 | Response to Walsh. <i>Journal of the National Cancer Institute</i> , 2019, 111, 748-748. | 6.3 | 0 |
| 39 | Poor Follow-up After Elevated Prostate-specific Antigen Tests: A Population-based Cohort Study. <i>European Urology Focus</i> , 2019, 5, 842-848. | 3.1 | 4 |
| 40 | The predictive value of DRE in the modern era of prostate cancer diagnostics.. <i>Journal of Clinical Oncology</i> , 2019, 37, 48-48. | 1.6 | 0 |
| 41 | Survival in men diagnosed with castration resistant prostate cancer: A population-based observational study in Sweden.. <i>Journal of Clinical Oncology</i> , 2019, 37, e16555-e16555. | 1.6 | 1 |
| 42 | The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential. <i>European Urology</i> , 2018, 74, 204-210. | 1.9 | 68 |
| 43 | Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 57-63. | 3.9 | 134 |
| 44 | Reply to Ola Bratt and Anna Åfverholm's Letter to the Editor re: Peter Stråm, Tobias Nordstråm, Henrik Grånberg, Martin Eklund. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential. <i>Eur Urol</i> . In press. https://doi.org/10.1016/j.eururo.2017.12.028 . <i>European Urology</i> , 2018, 74, e10-e11. | 1.9 | 0 |
| 45 | Risk of Prostate Cancer in Men Treated With 5 α -Reductase Inhibitors—A Large Population-Based Prospective Study. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1216-1221. | 6.3 | 27 |
| 46 | Balancing Overdiagnosis and Early Detection of Prostate Cancer using the Stockholm-3 Model. <i>European Urology Focus</i> , 2018, 4, 385-387. | 3.1 | 9 |
| 47 | The Stockholm-3 (STHLM3) Model can Improve Prostate Cancer Diagnostics in Men Aged 50-69 yr Compared with Current Prostate Cancer Testing. <i>European Urology Focus</i> , 2018, 4, 707-710. | 3.1 | 42 |
| 48 | Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis. <i>Genome Medicine</i> , 2018, 10, 85. | 8.2 | 94 |
| 49 | Towards Next-generation Urine-based Prostate Cancer Risk Stratification. <i>European Urology</i> , 2018, 74, 739-740. | 1.9 | 2 |
| 50 | Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging. <i>European Urology</i> , 2018, 74, 722-728. | 1.9 | 70 |
| 51 | Re: Tobias Nordstråm, Andrew Vickers, Melissa Assel, Hans Lilja, Henrik Grånberg, Martin Eklund. Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer. <i>Eur Urol</i> 2015;68:139-146. <i>European Urology</i> , 2018, 74, e35-e36. | 1.9 | 2 |
| 52 | Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. <i>Nature Genetics</i> , 2018, 50, 928-936. | 21.4 | 652 |
| 53 | Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. <i>Nature Communications</i> , 2018, 9, 2256. | 12.8 | 88 |
| 54 | Genome-wide association study of prostate-specific antigen levels identifies novel loci independent of prostate cancer. <i>Nature Communications</i> , 2017, 8, 14248. | 12.8 | 58 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | Detection of Prostate Cancer Using a Multistep Approach with Prostate-specific Antigen, the Stockholm 3 Test, and Targeted Biopsies: The STHLM3 MRI Project. <i>European Urology Focus</i> , 2017, 3, 526-528. | 3.1 | 14 |
| 56 | Future directions in prostate cancer testing: a comment upon results from the prospective population-based diagnostic STHLM3 study. GrÅnberg H et al. <i>Lancet Oncology</i> . 2015 Nov 9; doi:10.1016/S1470-2045(15)00361-7. <i>World Journal of Urology</i> , 2017, 35, 895-896. | 2.2 | 0 |
| 57 | Effects of increasing the PSA cutoff to perform additional biomarker tests before prostate biopsy. <i>BMC Urology</i> , 2017, 17, 92. | 1.4 | 3 |
| 58 | The STHLM3 prostate cancer diagnostic study: calibration, clarification, and comments. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 394-394. | 27.6 | 7 |
| 59 | Repeat Prostate-Specific Antigen Tests Before Prostate Biopsy Decisions. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw165. | 6.3 | 13 |
| 60 | Associations between circulating carotenoids, genomic instability and the risk of high-grade prostate cancer. <i>Prostate</i> , 2016, 76, 339-348. | 2.3 | 32 |
| 61 | A population-based study on the association between educational length, prostate-specific antigen testing and use of prostate biopsies. <i>Scandinavian Journal of Urology</i> , 2016, 50, 104-109. | 1.0 | 15 |
| 62 | Association of changing prostate-specific antigen (PSA) levels on repeat testing with lower risk for Gleason Score (GS) ≥ 7 prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 284-284. | 1.6 | 0 |
| 63 | Rapid increase in multidrug-resistant enteric bacilli blood stream infection after prostate biopsy-A 10-year population-based cohort study. <i>Prostate</i> , 2015, 75, 947-956. | 2.3 | 37 |
| 64 | The risk of prostate cancer for men on aspirin, statin or antidiabetic medications. <i>European Journal of Cancer</i> , 2015, 51, 725-733. | 2.8 | 61 |
| 65 | Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer. <i>European Urology</i> , 2015, 68, 139-146. | 1.9 | 156 |
| 66 | Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study. <i>Lancet Oncology</i> , The, 2015, 16, 1667-1676. | 10.7 | 308 |
| 67 | A Genetic Score Can Identify Men at High Risk for Prostate Cancer Among Men With Prostate-Specific Antigen of ≥ 3 ng/ml. <i>European Urology</i> , 2014, 65, 1184-1190. | 1.9 | 32 |
| 68 | Reply from Authors re: Goutham Vemana, Gerald L. Andriole. Bad Habits May Be Hard to Break. <i>Eur Urol</i> 2013;63:426-7. <i>European Urology</i> , 2013, 63, 427. | 1.9 | 0 |
| 69 | Prostate-specific Antigen (PSA) Testing Is Prevalent and Increasing in Stockholm County, Sweden, Despite No Recommendations for PSA Screening: Results from a Population-based Study, 2003-2011. <i>European Urology</i> , 2013, 63, 419-425. | 1.9 | 85 |